Overview

A Study of Effect of LY3556050 on Metformin in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-02-11
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate how much Metformin gets into the bloodstream and how long the body takes to get rid of it when it is administered orally in combination with LY3556050 in healthy participants. Iohexol will be administered to evaluate kidney function. Each enrolled participant will remain in the study for up to 7 weeks including the screening period.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Metformin